253 related articles for article (PubMed ID: 36307991)
21. M
Zhang Y; Gao LX; Wang W; Zhang T; Dong FY; Ding WP
Cancer Sci; 2022 Sep; 113(9):3085-3096. PubMed ID: 35730319
[TBL] [Abstract][Full Text] [Related]
22. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
[TBL] [Abstract][Full Text] [Related]
23. Chemical Inhibitors Targeting the Oncogenic m
Huang Y; Xia W; Dong Z; Yang CG
Acc Chem Res; 2023 Nov; 56(21):3010-3022. PubMed ID: 37889223
[TBL] [Abstract][Full Text] [Related]
24. FTO regulates myoblast proliferation by controlling CCND1 expression in an m
Deng K; Zhang Z; Ren C; Liang Y; Gao X; Fan Y; Wang F
Exp Cell Res; 2021 Apr; 401(2):112524. PubMed ID: 33651996
[TBL] [Abstract][Full Text] [Related]
25. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis.
Yue C; Chen J; Li Z; Li L; Chen J; Guo Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):240. PubMed ID: 33183350
[TBL] [Abstract][Full Text] [Related]
26. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
27. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract][Full Text] [Related]
28. Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil.
Liu T; Wang X; Hu W; Fang Z; Jin Y; Fang X; Miao QR
Neoplasia; 2019 Jun; 21(6):557-570. PubMed ID: 31042625
[TBL] [Abstract][Full Text] [Related]
29. m
Wang X; Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Shi H; Wang F; Wang Y
Autophagy; 2020 Jul; 16(7):1221-1235. PubMed ID: 31451060
[TBL] [Abstract][Full Text] [Related]
30. FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.
Zhao F; Ge F; Xie M; Li Z; Zang C; Kong L; Pu Y; Zheng X; Tan Y
Clin Exp Metastasis; 2022 Aug; 39(4):623-639. PubMed ID: 35524932
[TBL] [Abstract][Full Text] [Related]
31. N6-methyladenosine Demethylase FTO Induces the Dysfunctions of Ovarian Granulosa Cells by Upregulating Flotillin 2.
Zhou L; Han X; Li W; Wang N; Yao L; Zhao Y; Zhang L
Reprod Sci; 2022 Apr; 29(4):1305-1315. PubMed ID: 34254281
[TBL] [Abstract][Full Text] [Related]
32. N6-methyladenosine(m
Tang J; Su Q; Guo Z; Zhou J; Zheng F; Yu G; Shao W; Hu H; Wu S; Li H
Environ Pollut; 2022 Mar; 297():118749. PubMed ID: 34968619
[TBL] [Abstract][Full Text] [Related]
33. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
34. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.
Zhang L; Wan Y; Zhang Z; Jiang Y; Lang J; Cheng W; Zhu L
RNA Biol; 2021 Sep; 18(9):1265-1278. PubMed ID: 33103587
[TBL] [Abstract][Full Text] [Related]
35. FTO promotes the progression of retinoblastoma through YTHDF2-dependent N6-methyladenosine modification in E2F3.
Xie W; Shao Y; Bo Q; Li Z; Yu Q; Wang L; Wu G
Mol Carcinog; 2024 May; 63(5):926-937. PubMed ID: 38380957
[TBL] [Abstract][Full Text] [Related]
36. Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype 3 axis.
Gao Y; Liu C; Xu X; Wang Y; Jiang Y
Anticancer Drugs; 2022 Jul; 33(6):553-563. PubMed ID: 35276696
[TBL] [Abstract][Full Text] [Related]
37. FTO-mediated cytoplasmic m
Relier S; Ripoll J; Guillorit H; Amalric A; Achour C; Boissière F; Vialaret J; Attina A; Debart F; Choquet A; Macari F; Marchand V; Motorin Y; Samalin E; Vasseur JJ; Pannequin J; Aguilo F; Lopez-Crapez E; Hirtz C; Rivals E; Bastide A; David A
Nat Commun; 2021 Mar; 12(1):1716. PubMed ID: 33741917
[TBL] [Abstract][Full Text] [Related]
38. The antagonistic effect of FTO on METTL14 promotes AKT3 m
Wei R; Zhao F; Kong L; Pu Y; Li Y; Zang C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):131. PubMed ID: 38491196
[TBL] [Abstract][Full Text] [Related]
39. Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
Li X; Ma Y; Wu J; Ni M; Chen A; Zhou Y; Dai W; Chen Z; Jiang R; Ling Y; Yao Q; Chen W
Drug Resist Updat; 2023 Mar; 67():100930. PubMed ID: 36736043
[TBL] [Abstract][Full Text] [Related]
40. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.
Lin K; Zhou E; Shi T; Zhang S; Zhang J; Zheng Z; Pan Y; Gao W; Yu Y
J Exp Clin Cancer Res; 2023 Aug; 42(1):217. PubMed ID: 37605223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
